Shots:

• CEPI to invest $3.5M in Clover to support the initiation of P-I clinical study of its protein-based COVID-19 S-Trimer vaccine in Australia. The vaccine is based on Clover’s Trimer-Tag vaccine technology platform- used to produce the spike proteins of the COVID-19 virus in a native trimeric form for use in a vaccine
• The collaboration marks the CEPI’s ninth global COVID-19 vaccine development project since Jan 23- 2020.  If successful in clinical trials- the company will rapidly scale up the production of the vaccine utilizing its in-house biomanufacturing capabilities
• Additionally- CEPI has provided initial support and funding to Curevac- Inovio Pharmaceuticals- Moderna- Novavax- The University of Hong Kong- The University of Oxford- The University of Queensland and a consortium led by Institut Pasteur to develop COVID-19 vaccine candidates

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Clover Therapaeutics

Related News:    CEPI Collaborates with University of Hong Kong to Develop Vaccine for COVID-19